Vivifi Medical
Developing minimally invasive medical devices for urologic conditions like BPH and varicocele.
Website: https://www.vivifimedical.com/
Cover Block
From the public record
| Field | Detail |
|---|---|
| Company | Vivifi Medical |
| Tagline | Developing minimally invasive medical devices for urologic conditions like BPH and varicocele. [Vivifi Medical, retrieved 2026] |
| Headquarters | Houston, TX, USA [Crunchbase] |
| Founded | 2010 [Crunchbase] |
| Stage | Seed [Crunchbase] |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder [Vivifi Medical, retrieved 2026] |
| Founder | Tushar Sharma, PhD [Vivifi Medical, retrieved 2026] |
| Funding Label | Seed |
| Total Disclosed | Approximately $2.081 million in publicly identifiable non-dilutive awards (estimated), excluding undisclosed equity financing [Texas SBDC, Jan 2024; HigherGov, Sep 2025; LinkedIn, Feb 2026; Vivifi Medical] |
Links
From the public record
- Website: https://www.vivifimedical.com/
- LinkedIn: https://www.linkedin.com/company/vivifimedical
The Short Version
PUBLIC Vivifi Medical is a Houston-based medical device startup building minimally invasive treatments for urologic conditions, and it merits investor attention now because its public record shows a steady sequence of SBIR support, a recent venture check from Robinson Ventures, and early preclinical-to-clinical progression around BPH and varicocele programs [Crunchbase] [Robinson Ventures, May 2024] [HigherGov, September 2025]. Founded in 2010 by Tushar Sharma, PhD, the company has spent an unusually long gestation period on a narrow clinical wedge rather than pursuing a broad platform story, which makes progress on translational milestones more important than headline volume [Crunchbase] [Vivifi Medical].
The lead BPH program, ReFlow, is described by the company as an outpatient procedure intended to address vascular and hormonal drivers of prostate enlargement through a minimally invasive, non-transurethral approach, a position that, if borne out in clinical data, would place it outside the standard tissue-removal framing that defines much of the category today [Vivifi Medical] [Vivifi Medical, retrieved 2026]. A second program, Calexis-Lap, is presented by Robinson Ventures as a suture-less laparoscopic device for varicocele, giving the company a related men’s health adjacency rather than a wholly separate indication set [Robinson Ventures, May 2024].
Sharma remains the central figure in the public record as founder and CEO, with prior experience at Intel according to Crunchbase and medical-device-related patent activity surfaced in public patent search results, although broader operating bench depth is only lightly documented in public sources [Crunchbase] [Justia Patents Search, retrieved 2026]. That matters because, at this stage, execution risk is likely to sit less in concept formation than in trial design, regulatory sequencing, and eventual physician adoption.
The financing profile is still grant-heavy. Publicly identifiable non-dilutive awards sum to at least $2.081 million (estimated), based on a $256,000 NSF SBIR Phase I award, a $1 million NSF SBIR Phase II award, a $325,000 NIH/NIDDK SBIR award, and a reported $500,000 NSF SBIR Phase IIB award, while Robinson Ventures disclosed an equity investment in May 2024 without amount or valuation detail [Texas SBDC, January 2024] [Vivifi Medical] [HigherGov, September 2025] [LinkedIn, February 2026] [Robinson Ventures, May 2024]. Tracxn separately reports a $2.99 million seed round dated September 26, 2024, but that figure is not corroborated by the investor announcement in the materials reviewed here and should be treated cautiously until matched to primary financing documents or additional independent reporting [Tracxn].
Over the next 12 to 18 months, the key watch items are straightforward: whether Vivifi can convert company-described feasibility work and preclinical development into named first-in-human studies, whether regulatory status becomes clearer for ReFlow, and whether the company starts to show evidence of physician, site, or institutional partners beyond accelerator and award visibility [LinkedIn, February 2026] [Indexed.vc] [Business Wire, September 2026]. The opportunity is conceptually interesting, but public evidence remains weighted toward grants, company materials, and ecosystem recognition rather than commercial proof.
Single-source, plausible -- This section relies on a mix of company materials, investor announcements, grant databases, and startup data platforms, with several product and funding details only partially corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed, total disclosed approximately $2,081,000 in identifiable non-dilutive awards plus undisclosed equity investment [Texas SBDC, January 2024] [HigherGov, September 2025] [LinkedIn, February 2026] [Robinson Ventures, May 2024] |
The Company in Brief
PUBLIC
Vivifi Medical presents as a long-gestating urology device company rather than a newly formed AI-era startup. Public company materials and Crunchbase place the business in Houston and date its founding to 2010, with Tushar Sharma, PhD, identified as founder and chief executive [Crunchbase] [Vivifi Medical]. The company describes its focus in plain terms: minimally invasive devices for urologic conditions, with current public emphasis on benign prostatic hyperplasia and varicocele [Vivifi Medical].
The public milestone record is uneven, but the chronology is still readable. A Texas SBDC case study states that Vivifi received a $256,000 NSF SBIR Phase I award, which the company framed as an early inflection point for development work [Texas SBDC, January 2024]. Vivifi later announced an NSF SBIR Phase II award of $1 million for R&D related to laparoscopic devices for varicocele and related conditions, while Robinson Ventures disclosed an investment in May 2024 without stating the amount [Vivifi Medical] [Robinson Ventures, May 2024].
By 2026, the company was still in development mode rather than commercial scale-up. On its website, Vivifi said it had been selected for MedTech Innovator's 2026 cohort, and Crunchbase continued to profile the company as venture-backed but early stage [Vivifi Medical] [Crunchbase]. Taken together, the public record suggests a company that has stayed active through grant funding, accelerator participation, and at least one disclosed seed investment, while keeping a relatively low commercial profile [Vivifi Medical] [Crunchbase] [Robinson Ventures, May 2024].
Single-source, plausible -- Grounded primarily in Crunchbase and company website materials, with milestone support from Texas SBDC and Robinson Ventures.
What They Have Built
MIXED
Vivifi Medical is pursuing two urology device programs that are public in source materials, but the evidence base is uneven and still mostly pre-commercial. The lead program, ReFlow, is described by the company as an outpatient treatment for benign prostatic hyperplasia that takes roughly 10 to 15 minutes under local anesthesia and uses a minimally invasive, non-transurethral approach aimed at vascular and hormonal drivers rather than tissue removal [Vivifi Medical] [Indexed.vc]. Third-party research summaries and clinical-trial listings point in the same direction, describing a BPH procedure built around vascular anastomosis with a coupler and standard ligation, with initial studies focused on safety rather than commercial use [ClinicalTrial.be] [TrialX].
A second program, Calexis-Lap, broadens the platform logic into male infertility care. Robinson Ventures described it in May 2024 as a suture-less laparoscopic device for varicocele treatment, while BioAccess LA and Inknowvation characterized it as a vascular procedure intended for immediate and durable reversal, with a first-in-human study in Panama being planned [Robinson Ventures, May 2024] [BioAccess LA] [Inknowvation]. That framing is directionally interesting because it suggests Vivifi is not building a single point solution, but a procedural device approach around vascular intervention in urology; still, none of the public materials reviewed here establish FDA clearance, commercial deployment, or named health-system adoption for either product [Indexed.vc].
The software layer is less clearly documented than the device work. Public evidence therefore supports a company centered on minimally invasive medical devices, with only a tentative case for a companion software component.
Single-source, plausible -- Product descriptions are corroborated across company materials and third-party profiles, but several core claims remain company-originated and public evidence does not confirm regulatory clearance or commercial availability.
Market Size and Demand
From the public record This market matters because urology remains a high-volume procedural category, and startups that can shift treatment earlier, faster, or less invasively have a plausible path to clinician attention even before large-scale commercialization is proven.
The public evidence on Vivifi Medical's addressable market is narrower than investors would usually want for a full TAM model. The cleanest cited demand figure in the source set is on varicocele: approximately 30 million men in the U.S. are affected, with the condition linked to more than 1.5 million cases of infertility [BioAccess LA]. That is a condition prevalence datapoint rather than a procedure market estimate, and it should not be read as a revenue proxy. On the BPH side, the company positions ReFlow against a common urologic condition, but the materials provided here do not include a named third-party market size report for BPH devices or procedures, so any TAM, SAM, or SOM build would be premature on the public record.
A small sizing table is still useful because it shows where the current evidence is strongest and where it is not.
| Market lens | Public sizing claim | Interpretation |
|---|---|---|
| U.S. varicocele affected population | 30 million men [BioAccess LA] | Broad prevalence signal, not a treated population estimate |
| Infertility cases linked to varicocele | 1.5 million+ cases [BioAccess LA] | Suggests downstream clinical and economic burden |
The immediate read is that public market evidence is stronger for disease burden than for monetizable procedure volume. That can still support the case for clinical need, but it leaves reimbursement, adoption pacing, and provider workflow fit as open diligence items.
Demand drivers are easier to identify than precise market size. Vivifi's two target indications, BPH and varicocele, both sit in areas where patients and clinicians often weigh symptom burden, fertility outcomes, recovery time, and procedural invasiveness [Vivifi Medical] [Robinson Ventures, May 2024]. The company's core pitch, according to its website and investor materials, is that its BPH approach aims at vascular and hormonal drivers rather than conventional tissue removal, while Calexis-Lap is described as a suture-less minimally invasive approach for varicocele [Vivifi Medical] [Robinson Ventures, May 2024]. If that clinical framing holds up in formal studies, the commercial appeal would likely come from procedure simplification and a distinct mechanism of action rather than from software distribution or consumer pull.
There is also a timing tailwind in the company's funding history. Publicly identifiable support includes NSF and NIH SBIR awards across 2020, 2025, and 2026, plus an earlier company-announced NSF Phase II award [Texas SBDC, Jan 2024] [HigherGov, Sep 2025] [LSI USA / LinkedIn, Feb 2026] [Vivifi Medical]. Non-dilutive backing does not validate product-market fit, but it does suggest that public funding bodies see enough technical merit to support continued development. For a medtech startup working through clinical evidence generation, that matters because market entry is often gated by technical de-risking before it is gated by sales scale.
Adjacent and substitute markets are conceptually important here because Vivifi is not entering a blank space. For BPH, the practical substitutes are existing drug regimens and established procedural pathways, since the company itself frames ReFlow as an alternative to conventional tissue-removal surgery and long-term medication use [Vivifi Medical]. For varicocele, the adjacent market is male infertility intervention, where a device that changes operative technique would need to compete not only on efficacy but also on surgeon training, operating room workflow, and proof of durability [Robinson Ventures, May 2024] [BioAccess LA]. That means Vivifi's true competitive arena may be less about headline disease prevalence and more about whether it can convert incumbent procedural behavior in urology and related surgical settings.
Regulatory and macro forces make this a slower market than software investors sometimes expect. Public materials indicate that ReFlow was described as still under FDA investigation and not yet commercially available, and that Vivifi was reported to be planning first-in-human work for its varicocele treatment in Panama [Indexed.vc] [BioAccess LA]. The same source set also points to initial clinical studies designed to establish safety for the BPH approach rather than broad efficacy claims at commercial scale [TrialX]. That sequence is typical for device development, but it means market timing depends on evidence, regulatory progress, and physician adoption in that order. The market can be substantial, yet the investable question is less about need existing today and more about how quickly a new procedure can clear the clinical and regulatory thresholds required to matter.
Single-source, plausible -- Section relies on one named third-party prevalence source for varicocele burden, plus company, investor, and grant sources for market context and development-stage signals.
Who Else Is Fighting for This
MIXED Vivifi Medical is positioned less against a named startup set in the public record than against the established care pathways men already use for BPH and varicocele, which makes the competitive question primarily one of clinical substitution rather than feature comparison at this stage [Vivifi Medical] [Robinson Ventures, May 2024].
For BPH, the practical incumbent is the standard urology workflow, medication first and procedural escalation later, while Vivifi is arguing for a vascular and hormonal mechanism instead of tissue removal or ablation [Vivifi Medical] [TrialX]. Public materials also indicate that ReFlow is still investigational and not commercially available, so its current competition is not a directly named venture-backed peer so much as the status quo of approved treatment options and physician habit [Indexed.vc]. On the varicocele side, Calexis-Lap is described as a suture-less laparoscopic device, which places it against conventional laparoscopic or robotic surgical technique rather than an identified software or device startup cohort [Robinson Ventures, May 2024] [BioAccess LA].
That positioning creates a narrow but intelligible edge. The company has assembled at least $2.081 million in publicly identifiable non-dilutive awards (estimated) across NSF and NIH-linked programs, based on the disclosed grant amounts of $256,000 in 2020, $1,000,000 for NSF SBIR Phase II, $325,000 in 2025, and $500,000 in 2026 [Texas SBDC, Jan 2024] [Vivifi Medical] [HigherGov, Sep 2025] [LSI USA / LinkedIn, Feb 2026]. In medtech, that matters because grant capital can extend technical development without immediately forcing commercial proof. The durability is less clear. Grants help finance experimentation and early validation, but they do not by themselves create physician distribution, reimbursement coverage, or procedural adoption, so the edge is useful now and perishable later if clinical data do not convert into standard-of-care traction [HigherGov, Sep 2025] [LSI USA / LinkedIn, Feb 2026].
The exposure is easier to see than the moat. Because no named hospital customer, launch site, FDA clearance, or paying deployment appears in the public materials reviewed, Vivifi does not yet appear to control the channels that usually decide medtech outcomes: surgeon training, site onboarding, and regulatory timing [Robinson Ventures, May 2024] [Indexed.vc]. Robinson Ventures is a named backer and MedTech Innovator is a named accelerator relationship, but those are ecosystem signals rather than distribution assets [Robinson Ventures, May 2024] [Vivifi Medical]. A conventional incumbent care pathway is therefore the strongest competitive force in the near term, not because it is more novel, but because it is already approved, staffed, and embedded in urology practice.
The most plausible 18-month scenario is a split outcome across Vivifi's two programs. If the planned first-in-human varicocele work in Panama proceeds on schedule and produces interpretable safety data, Calexis-Lap is the most likely winner inside Vivifi's own portfolio because the product claim is narrower and the use case is easier to frame against existing laparoscopic workflow [BioAccess LA] [Robinson Ventures, May 2024]. If investigational timelines slip or the BPH program remains confined to feasibility evidence, the likely loser is ReFlow relative to incumbent BPH treatment pathways, since standard urology options keep the referral base and procedural volume by default while Vivifi continues to prove mechanism and operability rather than commercial readiness [Indexed.vc] [LSI USA / LinkedIn, Feb 2026].
Single-source, plausible -- Competitive analysis rests on company, investor, and third-party profile sources, but the public record reviewed does not name direct startup competitors or provide independent commercial market-share evidence.
Opportunity
PUBLIC
The prize here is not a niche device exit but a chance to define a new procedural lane in urology if Vivifi Medical can show that vascular and hormonal intervention changes outcomes in two large, persistent conditions, BPH and varicocele [Vivifi Medical] [BioAccess LA].
The headline opportunity is straightforward. If ReFlow can move from company description to reproducible clinical evidence, Vivifi could become an early platform company in minimally invasive urologic intervention, with one program in BPH and a second in male infertility-related varicocele [Vivifi Medical] [Robinson Ventures, May 2024]. That outcome is still conditional, but it is not purely aspirational. The company has been in development since 2010, has attracted repeated SBIR support across NSF and NIH, and has drawn at least one named venture investor, Robinson Ventures, into the story, which suggests external conviction beyond founder narrative alone [Crunchbase] [Texas SBDC, Jan 2024] [HigherGov, Sep 2025] [Robinson Ventures, May 2024]. Public materials also indicate that ReFlow is not yet commercially available and remains under FDA investigation, which narrows the claim to a development-stage opportunity rather than a near-term revenue ramp [Indexed.vc].
A practical way to think about upside is through a small number of path-dependent scenarios rather than a single base case.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| New procedural standard in BPH | ReFlow shows enough safety and procedural feasibility to earn broader clinical interest, giving Vivifi a foothold as a differentiated intervention for BPH rather than another tissue-removal tool | A successful first-in-human pilot and follow-on clinical readouts tied to the company's BPH program [TrialX] [LSI USA / LinkedIn, February 2026] | Vivifi publicly describes a non-transurethral BPH approach, and third-party coverage reports nine-patient feasibility work plus a planned 2026 pilot study, which is early but directionally supportive [Vivifi Medical] [LSI USA / LinkedIn, February 2026] |
| Dual-indication urology platform | The company advances both ReFlow for BPH and Calexis-Lap for varicocele, creating a broader urologic device platform with multiple entry points into surgeon workflow | First-in-human progress in varicocele and continued non-dilutive funding for the BPH program [BioAccess LA] [HigherGov, Sep 2025] | Public sources already show two distinct product tracks, one aimed at BPH and one at varicocele, with independent external references rather than a single website-only claim [Robinson Ventures, May 2024] [BioAccess LA] |
| Capital-efficient medtech builder | Vivifi uses grants and accelerator visibility to derisk technical milestones before larger equity financings, preserving ownership while increasing strategic value | Continued SBIR wins and ecosystem selection such as MedTech Innovator [Texas SBDC, Jan 2024] [HigherGov, Sep 2025] [Vivifi Medical] | The company has a visible history of grant funding across phases and agencies, with publicly identifiable non-dilutive awards of at least $2.081 million (estimated) based on disclosed grants of $256,000, $1,000,000, $325,000, and $500,000 [Texas SBDC, Jan 2024] [Vivifi Medical] [HigherGov, Sep 2025] [LSI USA / LinkedIn, February 2026] |
The compounding mechanism, if it emerges, would look like classic medtech de-risking rather than software network effects. One clinical proof point can support the next grant, one grant can finance the next study, and each study can make later equity capital or strategic partnerships easier to win. There is some evidence that this loop has started: public records show an early NSF SBIR Phase I award, a company-announced NSF Phase II award, a later NIH/NIDDK SBIR grant, and a reported NSF Phase IIB award, which together suggest a pattern of milestone-based external validation even before commercialization [Texas SBDC, Jan 2024] [Vivifi Medical] [HigherGov, Sep 2025] [LSI USA / LinkedIn, February 2026]. If that progression continues, Vivifi's advantage may come less from raw distribution and more from procedural know-how, patent coverage, and surgeon familiarity built across adjacent urologic indications [Vivifi Medical] [Justia Patents Search].
The size of the win is easiest to frame from disease burden rather than current company scale. BioAccess LA cites an addressable U.S. varicocele population of approximately 30 million men and more than 1.5 million infertility cases, which is a large enough clinical burden to support a meaningful device company if adoption and reimbursement follow [BioAccess LA]. BPH is also a large, established urology market, although no third-party TAM figure is available in the provided source set, so precision should stop there. Under the strongest scenario, where ReFlow establishes a defensible procedural category in BPH and Calexis-Lap opens a second urology franchise, the company could plausibly grow into a strategic acquisition target or standalone specialty medtech asset worth several hundred million dollars to low single-digit billions of dollars (scenario, not a forecast). That valuation range is an inference from the scale of the treated conditions and the presence of multi-program optionality, not from disclosed revenue, clearance, or commercial traction, none of which are established in the public record here [BioAccess LA] [Indexed.vc] [Robinson Ventures, May 2024].
Single-source, plausible -- Built primarily from company materials and a small set of independent public sources, including Robinson Ventures, Texas SBDC, HigherGov, BioAccess LA, and third-party profiles; key product and clinical claims remain only partially corroborated.
Sources
From the public record
[Vivifi Medical, retrieved 2026] Revolutionary BPH Treatment | Vivifi Medical | https://www.vivifimedical.com/
[Crunchbase, retrieved 2026] Vivifi Medical - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/vivifi-medical
[Texas SBDC, Jan 2024] VIVIFI MEDICAL | https://tcc.txsbdc.org/wp-content/uploads/2024/01/Vivify-story.pdf
[HigherGov, Sep 2025] R43DK139847 grant listing | https://www.highergov.com/grant/R43DK139847/
[LinkedIn, Feb 2026] Vivifi Medical Develops Non-Surgical BPH Treatment | https://www.linkedin.com/posts/lsi-usa_vivifi-medical-is-developing-a-first-in-class-activity-7425236816607264768-55T1
[Robinson Ventures, May 2024] ROBINSON VENTURES INVESTS IN VIVIFI MEDICAL | https://www.robinsonventures.com/news/article/current/2024/05/17/100043/robinson-ventures-invests-in-vivifi-medical
[Justia Patents Search, retrieved 2026] Justia Patents Search | https://patents.justia.com/search?q=Tushar+Sharma
[Tracxn, retrieved 2026] Vivifi Medical - 2025 Company Profile, Team, Funding & Competitors - Tracxn | https://tracxn.com/d/companies/vivifi-medical/__FvoWC_LFryZ6EMOmxLikCIwv7wFhiOXf052F7lZk7Qo
[Business Wire, Sep 2026] Pepperdine Graziadio Business School Announces 2026 Most Fundable Companies® | https://www.businesswire.com/news/home/20260924133294/en/Pepperdine-Graziadio-Business-School-Announces-2026-Most-Fundable-Companies
[Indexed.vc, retrieved 2026] Vivifi Medical LLC | https://indexed.vc/companies/vivifi-medical-llc
[ClinicalTrial.be, retrieved 2026] Vivifi BPH clinical trial listing | https://clinicaltrial.be/
[TrialX, retrieved 2026] Vivifi BPH trial listing | https://www.trialx.com/
[BioAccess LA, retrieved 2026] BioAccess LA coverage of Vivifi Medical | https://www.bioaccessla.org/
[Inknowvation, retrieved 2026] Inknowvation coverage of Vivifi Medical | https://inknowvation.com/
Articles about Vivifi Medical
- Vivifi Medical's Non-Surgical BPH Bet Lands Over $2 Million in Federal Grants — The Houston startup is using SBIR funding to develop a vascular approach to prostate enlargement, with a first-in-human trial planned.